Plain-English translation of NCT07619118 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This study is testing a new medication called laroprovstat combined with rosuvastatin (a common cholesterol drug) to see if it lowers cholesterol better than rosuvastatin alone. You would take either the combination medication or rosuvastatin by itself, depending on which group you're randomly assigned to. Researchers want to understand if adding this new drug helps patients manage their cholesterol more effectively.
High cholesterol is a major risk factor for heart disease, and many people don't reach their cholesterol goals with current treatments alone. This trial is exploring whether this medication can be a more powerful tool to help protect people from heart attacks and strokes.
You likely qualify if…
You likely don't qualify if…
You will take a daily pill—either the new combination medication or the standard cholesterol drug—along with placebo pills to keep the study blinded so neither you nor researchers know which group you're in. The study involves different dose levels, so your dose may be adjusted during the trial. You'll have regular visits to have blood tests done and discuss any side effects or concerns with the research team.
AI-generated summary from trial data · Oct 7, 2026 · Not medical advice
United States